Lexeo Therapeutics SUNRISE-FA 2 Trial Update

Written By Victoria Rogan

Lexeo Therapeutics have shared the message below for our FA Community on their Friedreich ataxia program based on highlights from their first quarter 2026 results.

Victoria Rogan
Previous

Design Therapeutics RESTORE-FA Trial Update
Next

Dynamic Balance in Friedreich Ataxia Study